留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

MiR-96和miR-424-5p在结直肠癌患者血清中的表达水平及临床意义

王梅 张琳 崔发财 毋小玉

王梅, 张琳, 崔发财, 毋小玉. MiR-96和miR-424-5p在结直肠癌患者血清中的表达水平及临床意义[J]. 中华全科医学, 2022, 20(5): 828-831. doi: 10.16766/j.cnki.issn.1674-4152.002465
引用本文: 王梅, 张琳, 崔发财, 毋小玉. MiR-96和miR-424-5p在结直肠癌患者血清中的表达水平及临床意义[J]. 中华全科医学, 2022, 20(5): 828-831. doi: 10.16766/j.cnki.issn.1674-4152.002465
WANG Mei, ZHANG Lin, CUI Fa-cai, WU Xiao-yu. The expression level of serum miR-96 and miR-424-5p in patients with colorectal cancer and its clinical significance[J]. Chinese Journal of General Practice, 2022, 20(5): 828-831. doi: 10.16766/j.cnki.issn.1674-4152.002465
Citation: WANG Mei, ZHANG Lin, CUI Fa-cai, WU Xiao-yu. The expression level of serum miR-96 and miR-424-5p in patients with colorectal cancer and its clinical significance[J]. Chinese Journal of General Practice, 2022, 20(5): 828-831. doi: 10.16766/j.cnki.issn.1674-4152.002465

MiR-96和miR-424-5p在结直肠癌患者血清中的表达水平及临床意义

doi: 10.16766/j.cnki.issn.1674-4152.002465
基金项目: 

河南省医学科技攻关计划项目 201702220

详细信息
    通讯作者:

    毋小玉,E-mail:47509197@qq.com

  • 中图分类号: R730.43 R446

The expression level of serum miR-96 and miR-424-5p in patients with colorectal cancer and its clinical significance

  • 摘要:   目的  分析血清miR-96和miR-424-5p表达与结直肠癌患者临床病理特征及预后的关系,探究两者联合检测对结直肠癌的诊断价值。  方法  收集2015年1—12月河南省人民医院收治的120例结直肠癌患者、40例结直肠腺瘤患者及40例健康受试者血清,采用实时荧光定量PCR(RT-PCR)方法检测血清miR-96和miR-424-5p的表达水平,分析其与结直肠癌患者临床病理特征及预后的关系,构建受试者工作特征(ROC)曲线评估血清miR-96和miR-424-5p的诊断效能。  结果  MiR-96和miR-424-5p在结直肠癌患者血清中的表达水平显著高于结直肠腺瘤患者和健康受试者,差异有统计学意义(均P < 0.05);TNM分期Ⅲ/Ⅳ期、低分化和有远处转移患者血清miR-96表达水平显著高于TNM分期Ⅰ/Ⅱ期、高中分化和无远处转移患者(均P < 0.01);TNM分期Ⅲ/Ⅳ期患者血清miR-424-5p表达水平显著高于TNM分期Ⅰ/Ⅱ期患者(均P < 0.01)。血清miR-96和miR-424-5p高表达患者的5年生存率及平均生存时间均低于血清miR-96和miR-424-5p低表达患者(均P < 0.01)。MiR-96和miR-424-5p诊断结直肠癌的曲线下面积(AUC)分别为0.727和0.720,特异性分别为71.2%和86.2%,两者联合检测的AUC和特异性分别为0.780和93.7%,均大于两者单独诊断(均P < 0.05)。  结论  血清miR-96和miR-424-5p表达水平升高与结直肠癌的发生、发展及预后不良相关,联合检测血清miR-96和miR-424-5p对于结直肠癌的诊断具有一定的参考价值。

     

  • 图  1  血清miR-96高表达组与低表达组结直肠癌患者的生存曲线

    Figure  1.  Survival curves of colorectal cancer patients with high and low expression of serum miR-96

    图  2  血清miR-424-5p高表达组与低表达组结直肠癌患者的生存曲线

    Figure  2.  Survival curves of colorectal cancer patients with high and low expression of serum miR-424-5p

    图  3  血清miR-96和miR-424-5p检测对CRC患者的诊断效能

    Figure  3.  Diagnostic efficacy of serum miR-96 and miR-424- 5P in patients with CRC

    表  1  血清miR-96和miR-424-5p表达水平与结直肠癌临床病理特征的关系(x±s)

    Table  1.   Relationship between the expression levels of serum miR-96 and miR-424- 5P and clinicopathological features of colorectal cancer(x±s)

    项目 例数 miR-96 t P miR-424-5p t P
    性别
      男性 72 1.29±0.48 1.280 0.203 1.16±0.36 0.766 0.446
      女性 48 1.18±0.45 1.11±0.30
    年龄(岁)
      ≤60 58 1.25±0.46 0.212 0.832 1.12±0.34 0.429 0.669
       > 60 62 1.27±0.49 1.15±0.34
    肿瘤直径(cm)
      ≤3 55 1.25±0.54 0.269 0.789 1.13±0.37 0.167 0.867
       > 3 65 1.27±0.43 1.14±0.31
    肿瘤发病部位
      结肠 46 1.31±0.52 0.915 0.362 1.18±0.30 1.046 0.298
      直肠 74 1.23±0.44 1.11±0.36
    TNM分期
      Ⅰ~Ⅱ期 66 1.14±0.41 3.061 0.003 1.06±0.32 2.710 0.008
      Ⅲ~Ⅳ期 54 1.40±0.52 1.23±0.33
    分化程度
      高/中分化 78 1.14±0.36 4.093 < 0.001 1.10±0.34 1.724 0.087
      低分化 42 1.49±0.58 1.21±0.31
    淋巴结转移
      无 61 1.18±0.43 1.859 0.065 1.09±0.32 1.696 0.093
      有 59 1.34±0.51 1.19±0.34
    远处转移
      无 94 1.19±0.41 3.350 0.001 1.11±0.34 1.579 0.117
      有 26 1.53±0.62 1.23±0.32
    下载: 导出CSV
  • [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. doi: 10.3322/caac.21492
    [2] SIEGEL R L, MILLER K D, GODING SAUER A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 145-164. doi: 10.3322/caac.21601
    [3] LU T X, ROTHENBERG M E. MicroRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207. doi: 10.1016/j.jaci.2017.08.034
    [4] RAPADO-GONZÁLEZ Ó ÁLVAREZ-CASTRO A, LÓPEZ-LÓPEZ R, et al. Circulating microRNAs as promising biomarkers in colorectal cancer[J]. Cancers (Basel), 2019, 11(7): 898. doi: 10.3390/cancers11070898
    [5] SUN Y, LIU Y, COGDELL D, et al. Examining plasma microRNA markers for colorectal cancer at different stages[J]. Oncotarget, 2016, 7(10): 11434-11449. doi: 10.18632/oncotarget.7196
    [6] HE P Y, YIP W K, JABAR M F, et al. Effect of the miR-96-5p inhibitor and mimic on the migration and invasion of the SW480-7 colorectal cancer cell line[J]. Oncol Lett, 2019, 18(2): 1949-1960.
    [7] 胡思锋, 王庆光, 李耀锋, 等. 微小RNA-96对结直肠癌细胞迁移及侵袭的影响[J]. 中华实验外科杂志, 2019, 36(1): 83-85. doi: 10.3760/cma.j.issn.1001-9030.2019.01.026

    HU S F, WANG Q G, LI Y F, et al. Effect of miR-96 on migration and invasion of colorectal cancer cells[J]. Chinese Journal of Experimental Surgery, 2019, 36(1): 83-85. doi: 10.3760/cma.j.issn.1001-9030.2019.01.026
    [8] GE T, XIANG P, MAO H, et al. Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1[J]. Exp Ther Med, 2020, 20(3): 2134-2140.
    [9] DASTMALCHI N, HOSSEINPOURFEIZI M A, KHOJASTEH S M B, et al. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway[J]. Life Sci, 2020, 259: 118239. doi: 10.1016/j.lfs.2020.118239
    [10] MA L L, LIANG L, ZHOU D, et al. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4[J]. Neoplasma, 2020, 8: 200707N705.
    [11] ZHAO C, ZHAO F, CHEN H, et al. microRNA-424-5p inhibits the proliferation, migration, and invasion of nasopharyngeal carcinoma cells by decreasing AKT3 expression[J]. Braz J Med Biol Res, 2020, 53(7): e9029. doi: 10.1590/1414-431x20209029
    [12] 王红, 曹梦迪, 刘成成, 等. 中国人群结直肠癌疾病负担: 近年是否有变?[J]. 中华流行病学杂志, 2020, 41(10): 1633-1642. doi: 10.3760/cma.j.cn112338-20200306-00273

    WANG H, CAO M D, LIU C C, et al. Disease burden of colorectal cancer in China: Any changes in recent years?[J]. Chinese Journal of Epidemiology, 2020, 41(10): 1633-1642. doi: 10.3760/cma.j.cn112338-20200306-00273
    [13] 吴春晓, 顾凯, 龚杨明, 等. 2015年中国结直肠癌发病和死亡情况分析[J]. 中国癌症杂志, 2020, 30(4): 241-245. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202004001.htm

    WU C X, GU K, GONG Y M, et al. Analysis of incidence and mortality of colorectal cancer in China, 2015[J]. China Oncology, 2020, 30(4): 241-245. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202004001.htm
    [14] LONG J L, HE Q L, YIN YT, et al. The effect of miRNA and autophagy on colorectal cancer[J]. Cell Prolif, 2020, 53(10): e12900.
    [15] YIN X L, CHAI Z T, SUN X T, et al. Overexpression of microRNA-96 is associated with poor prognosis and promotes proliferation, migration and invasion in cholangiocarcinoma cells via MTSS1[J]. Exp Ther Med, 2020, 19(4): 2757-2765.
    [16] NING S F, LIU H Z, GAO B, et al. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma[J]. Oncol Lett, 2019, 18(3): 3381-3387.
    [17] CHENG Z, SHU H S, CUI Y, et al. MiR-424-5p inhibits proliferation, invasion and promotes apoptosis and predicts good prognosis in glioma by directly targeting BFAR[J]. Pathol Oncol Res, 2020, 26(4): 2327-2335. doi: 10.1007/s12253-020-00831-1
    [18] YUE C F, CHEN J R, LI Z Y, et al. microRNA-96 promotes occurrence and progression of colorectal cancer via regulation of the AMPKα2-FTO-m6A/MYC axis[J]. J Exp Clin Cancer Res, 2020, 39(1): 240. doi: 10.1186/s13046-020-01731-7
    [19] SAHAMI-FARD M H, KHEIRANDISH S, SHEIKHHA M H. Expression levels of miR-143-3p and miR-424-5p in colorectal cancer and their clinical significance[J]. Cancer Biomark, 2019, 24(3): 291-297. doi: 10.3233/CBM-182171
  • 加载中
图(3) / 表(1)
计量
  • 文章访问数:  162
  • HTML全文浏览量:  42
  • PDF下载量:  3
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-09-11
  • 网络出版日期:  2022-09-05

目录

    /

    返回文章
    返回